This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Uveitis  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Chrysanthi Kafkala, MD; John Y. Choi, MD; Pitipol Choopong, MD; C. Stephen Foster, MD

Arch Ophthalmol. 2006;124:1353-1355.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Cystoid macular edema (CME) is the most frequent cause of irreversible blindness and visual impairment in patients with uveitis.¹ There is no consensus on the most effective treatment for uveitis-associated CME; many agents are used with variable responses. Because there is a constant release of inflammatory mediators that can disturb retinal pigment epithelial pump function in active uveitis, the first and most important step is to control the uveitis. In addition, CME can be treated with conventional options, including corticosteroid agents administered topically, by periocular or intraocular injection, or orally; nonsteroidal anti-inflammatory drugs administered orally or topically in aphakic eyes; and carbonic anhydrase inhibitors. Additional treatment methods such as hyperbaric oxygen, pars plana vitrectomy, and laser grid photocoagulation are more controversial treatments. Despite aggressive treatment, CME frequently progresses.

Octreotide is a somatostatin analogue. It is an . . . [Full Text of this Article]

Methods


Results

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?